Canaccord Maintains Buy Rating on Compass Therapeutics Despite Lowered Price Target
On April 28, 2026, Canaccord lowered its price target for Compass Therapeutics (NASDAQ:CMPX) to $7 from $13 but maintained a 'Buy' rating. The firm noted mixed clinical trial results and potential regulatory hurdles with the FDA regarding overall survival data.
Topics: Biopharmaceuticals Clinical Trials FDA Approval Outlook